Ayman Iskander, MD
Cardiovascular Disease · Liverpool, NYNPI 1972599728
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 67.1% of it on its own, with 31 other manufacturers making up the rest. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $95.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$25K
- Medtronic$5K
- Inari Medical, Inc.$1K
- Abbott$1K
- Boston Scientific$832
- Abiomed$603
- plus $3K from 26 others
Across 129 payments — averaging $9938.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$967K
- CSL Behring$93K
- Boehringer Ingelheim International GmbH$88K
- Boehringer Ingelheim Pharma GmbH & Co.kg$81K
- W. L. Gore & Associates, Inc.$52K
What the payments were for
- Consulting fees$7,39020%
- Travel & lodging$15,31442%
- Food & beverage$14,01538%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 148 | $24,621 |
| Medtronic(2 entities) | 40 | $4,962 |
| Inari Medical, Inc. | 6 | $1,398 |
| Abbott | 22 | $1,086 |
| Boston Scientific | 16 | $832 |
| Abiomed | 17 | $603 |
| Amgen | 22 | $417 |
| AstraZeneca | 17 | $382 |
| Penumbra, Inc. | 6 | $356 |
| Thrombolex, Inc. | 4 | $350 |
| Johnson & Johnson | 15 | $217 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $206 |
| Pfizer | 11 | $175 |
| Merck | 9 | $160 |
| Actelion Pharmaceuticals US, Inc. | 6 | $122 |
| W. L. Gore & Associates, Inc. | 1 | $96 |
| Lexicon Pharmaceuticals, Inc. | 5 | $90 |
| Novartis | 5 | $88 |
| Biotronik Inc. | 2 | $76 |
| Atricure, Inc. | 1 | $73 |
| Shockwave Medical, Inc | 2 | $69 |
| Boehringer Ingelheim | 3 | $69 |
| Bayer | 3 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Philips North America LLC | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Cardiovascular Systems Inc. | 1 | $23 |
| Angiodynamics, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$9,439
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$3,809
- Resolute$3,041
- SAPIEN 3 Ultra RESILIA$2,815
- FlowTriever$977
- ClotTriever$977
- NAVITOR$406
- FLOWTRIEVER CATHETER, S$317
- EVOQUE$212
- LOTUS EDGE$205
- Confirm Rx$163
- CoreValve Evolut$163
- ONYX FRONTIER$133
- COREVALVE EVOLUT R$130
- Watchman$128
- Micra$124
- EKOSONIC$123
- Bashir Endovascular Catheter$111
- SYMPLICITY G3$110
- AMPLATZER AMULET$101
How this compares
$36,719 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 174 | $2,112 |
| Ezetimibe | 11 | $454 |
| Atorvastatin Calcium | 20 | $293 |
| Rosuvastatin Calcium | 21 | $210 |
| Metoprolol Tartrate | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Liverpool
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.